Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialAnn. Oncol 2023 Aug 17;[EPub Ahead of Print], K Jhaveri, LD Eli, H Wildiers, SA Hurvitz, A Guerrero-Zotano, N Unni, A Brufsky, H Park, J Waisman, ES Yang, I Spanggaard, S Reid, ME Burkard, S Vinayak, A Prat, M Arnedos, FC Bidard, S Loi, J Crown, M Bhave, SA Piha-Paul, JM Suga, S Chia, C Saura, JÁ Garcia-Saenz, V Gambardella, MJ de Miguel, EN Gal-Yam, A Rapael, SM Stemmer, C Ma, AB Hanker, D Ye, JW Goldman, R Bose, L Peterson, JSK Bell, A Frazier, D DiPrimeo, A Wong, CL Arteaga, DB Solit
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.